1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Does Prothena Have A Best-In-Class Alzheimer’s Drug Waiting In The Wings?

Candidate 20 Times More Potent Than Leqembi In Preclinical Studies

 
• By Andrew McConaghie

More than 20 years since its forerunner tried to develop the first anti-amyloid drug, Prothena’s CEO tells Scrip about its hopes for producing a best-in-class subcutaneous treatment for Alzheimer’s disease.

Prothena

Alzheimer’s disease treatment is finally set to be transformed following the recent US approval of Eisai and Biogen’s Leqembi, and the upcoming approval decision for Eli Lilly’s donanemab, but given their drawbacks many in the field are looking ahead to see if other companies can build on their modest clinical benefits. (Also see "Lilly’s Donanemab, Now At FDA, Poised To Join Alzheimer’s Armamentarium" - Scrip, 17 July, 2023.)

Among a handful of pipeline contenders, analysts are particularly excited about Prothena and its lead candidate, PRX12

More from Clinical Trials

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

More from R&D